← Back to Search

Behavioural Intervention

Children with Hearing Loss for Sensorineural Hearing Loss (SoftSpeech Trial)

N/A
Waitlist Available
Research Sponsored by Sonova AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 of 1 day study
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new hearing aid feature called Soft Speech Enhancer to help children with moderate to severe hearing loss hear quiet speech better. The feature amplifies soft sounds, making it easier for these children to understand words and improve their language skills.

Eligible Conditions
  • Sensorineural Hearing Loss
  • Bilateral Hearing Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 of 1 day study
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 of 1 day study for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Speech Recognition in Quiet Using CNC (Consonant-Nucleus-Consonant) Word Lists
Secondary study objectives
Subjective Ratings of Speech Enhancer

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Children with Hearing LossExperimental Treatment1 Intervention
Participants age 5-12 with hearing loss who will be fit with study hearing aids and tested on speech perception in unaided and aided condition.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phonak Audeo P or Naida P hearing aid
2022
N/A
~40

Find a Location

Who is running the clinical trial?

Hearts for HearingUNKNOWN
5 Previous Clinical Trials
160 Total Patients Enrolled
Sonova AGLead Sponsor
80 Previous Clinical Trials
1,892 Total Patients Enrolled
~10 spots leftby Nov 2025